2024年短期課程* （僅限線下面對面形式）

* 需單獨申請。

本會議的短期課程旨在具有教育性、互動性，並提供有關特定領域的深入資訊，且可隨時提問和回答。這個短期課程除了為初學者和想要瞭解更多資訊的人介紹該領域概論，更有在會議發表期間因時間限制而無法涵括的更技術方面的闡述。我們的講師精選自工業界和學術界，多數皆是該領域公認的權威，擁有豐富的指導經驗。

2024年10月15日（二） 9:00 - 12:00 pm

SC1: Development of NAb Assays, Technical Considerations, Case Studies

The development of neutralizing antibody assays is a daunting task that is complicated by the specific nature of each biotherapeutic. Many factors must be assessed to choose the proper assay format, to develop a robust assay, and choose when to invest in the development and implementation of these assays. This short course will focus on these topics and provide examples of current industry practices and publications.

9:00 am

Development of NAb Assays, Technical Considerations, Case Studies

Lynn Kamen, PhD, Scientific Officer, Executive Director, BioAgilytix

Jim McNally, PhD, CSO, BioAgilytix

Topics to be Covered Include:

Current regulatory guidance
NAb assay strategy - Immunogenicity risk assessment
Special focus on assay format selection - Mechanism of action-based approach
Validation and implementation of NAb assays
Relevant case studies

INSTRUCTOR BIOGRAPHIES:

Lynn Kamen, PhD, Scientific Officer, Executive Director, BioAgilytix

Lynn Kamen is a Scientific Officer at BioAgilytix. She earned her PhD in Immunology at the University of Michigan and completed a postdoctoral fellowship in immunology at the University of California, San Francisco. Lynn has over a decade of experience working in drug development, from early target discovery through clinical development for both large and small molecules at several companies including Portola Pharmaceuticals, and Alector. More recently, Lynn was a principal scientist at Genentech where she supported the in vitro biological characterization of large molecules and lead the development of immunogenicity assays including ADA, NAb and immunogenicity risk ranking assays. She is co-lead of the AAPS NAber working group and member of the AAPS NAb drug tolerance sub-team.

Jim McNally, PhD, CSO, BioAgilytix

Dr. McNally has an extensive background in bioanalytical assay development and program leadership spanning nearly 20 years working in the pharmaceutical and biotechnology industry. Prior to joining BioAgilytix, Dr. McNally was Executive Director at CRISPR Therapeutics, where he lead a team of scientists to develop a portfolio of assays to support development of gene-based therapeutic candidates throughout their lifecycle. He has also previously held roles at Genzyme, Pfizer, EMD Serono, and Shire which have given him broad experience in the development of large molecule, gene therapy, and cell therapy biotherapeutics. Dr. McNally is a recognized thought leader in the development and application of bioanalytical methods used in regulatory submissions and is specifically skilled in progression of biotherapeutics from research through clinical development. He has a special interest in the immunogenicity of biotherapeutics and leads an industry-wide working group to address this issue. A key part of his role at BioAgilytix is advising on emerging scientific developments and providing scientific and regulatory guidance. Dr. McNally obtained his B.S. in Biology from Mississippi State University, his Ph.D. Viral Immunology from Louisiana State University School of Medicine in Shreveport, and his Post-Doc in Viral Immunology from University of Massachusetts Medical School.

2024年10月15日（二） 2:00 - 5:00 pm

SC2: Overcoming Drug and Target Interference in ADA and NAb Assays

Soluble drug, drug target, and matrix can often interfere in the detection of anti-drug antibodies, including neutralizing Abs. Although not always straightforward, it can be addressed and mitigated in a properly designed immunoassay. This short course will give an overview of the different types of interferences, and current methodologies and approaches being utilized to resolve or reduce them.

2:00 pm

Overcoming Drug and Target Interference in ADA and NAb Assays

Lynn Kamen, PhD, Scientific Officer, Executive Director, BioAgilytix

Weifeng Xu, PhD, Director, Bioanalytical, Merck

Topics to be Covered Include:

Types of Interferences:

> Soluble Target

> Drug

> Matrix

Immunogenicity Assay Designs and Susceptibility to Interference
Competitive Ligand-Binding Immunoassays Bridging Immunoassays
Cell-Based Immunoassays Mitigation Strategies
Sample Pre-Treatment BEADACEBEHD
Heat Inactivation
Case Studies

INSTRUCTOR BIOGRAPHIES:

Lynn Kamen, PhD, Scientific Officer, Executive Director, BioAgilytix

Weifeng Xu, PhD, Director, Bioanalytical, Merck

Weifeng has been in the field of immunogenicity for biologics for about 10 years. He had developed cell-based neutralization Ab assays for multiple key product at BMS including Opdivo and Yervoy. He is an active member in AAPS NAb work group as well as EBA NAb team; he is also co-leading the NAb assay drug tolerance subteam at AAPS. After join Merck at the end of 2018, Weifeng is now leading Cell Assay group within PPDM Regulated Immunogenicity to develop neutralizing assays for both biologics and vaccines.

2024年10月15日（二） 5:30 - 8:30 pm

SC3: Validation of ADA Assays and Cut Point Calculations

This short course will focus on the validation of ADA assays and cut-point evaluations. We will provide an in-depth overview of the basic considerations around ADA assay validation, with significant focus on the process of evaluating different types of cut-points, and the translation of the cut-point established during validation to the real-world implementation during a preclinical or clinical study.

5:30 pm

Validation of ADA Assays and Cut-Point Calculations

Kavitha Akula, PhD, Principal Scientist, Bristol Myers Squibb Co.

Krupa Ramani, Senior Scientist, Janssen

Jiangbo Tang, PhD, Senior Scientist, Bristol Myers Squibb Co.

Topics to Be Covered Include:

Tiered testing strategy: Basic issues regarding screening, confirmatory, and titer assays
ADA assay validation strategies: Experimental design to execute a validation
Step-wise process for calculating different types of cut-points
Practical challenges for the in-study implementation of cut-points
Case studies related to the implementation of validation and study-specific cut-points

INSTRUCTOR BIOGRAPHIES:

Kavitha Akula, PhD, Principal Scientist, Bristol Myers Squibb Co.

Dr. Kavitha Akula is currently a Principal Scientist at Bristol-Myers Squibb (BMS) in the Non-clinical Disposition and Bioanalysis Group. Kavitha joined BMS in 2019 as Research Investigator-II with about five years of experience in regulated bioanalysis from different contract research organizations (CRO). She received her PhD from Temple University, Philadelphia in Organic Chemistry in 2017. Kavitha has extensive experience in regulate bioanalysis of large molecule drugs and new treatment modalities in support of PK and Immunogenicity. She recently took co-lead position in the Early Career Bioanalytical Scientists (ECBS) sub-team in AAPS.

Krupa Ramani, Senior Scientist, Janssen

Jiangbo Tang, PhD, Senior Scientist, Bristol Myers Squibb Co.

Jiangbo Tang is a Senior Scientist in the Department of Clinical Pharmacology, Pharmacometrics, Disposition & Bioanalysis at Bristol Myers Squibb (BMS). He leads regulated PK and immunogenicity bioanalytical development to support programs in CAR T, ADC, and antibody therapeutics. Prior to joining BMS, for several years he led a team at a CRO and provided regulated bioanalytical support for clinical programs. He also worked as a Staff Scientist in the QC Department at Regeneron, where he automated potency assays in support of stability, and lot release of drug products. Jiangbo received his PhD in Human Genetics from the University of Pittsburgh and completed his postdoc training at the University of Pennsylvania, where his published research in cancer biology and immunology has been widely cited with over 1,500 citations.

SC4: Recent Advances with Cell and Gene Therapy

Topics to be covered in this course include: Immunogenicity assessment of cell therapies, examining recent developments with CAR T cells & edited stem cell, immunogenicity assessment of gene therapies, recent data on pre-existing reactivity for AAV, advances with redosing, application of current guidance to novel modalities, and what is your product, the vector, the expressed product?

5:30 pm

Recent Advances with Cell and Gene Therapy

Jim McNally, PhD, CSO, BioAgilytix

Topics to be Covered Include:

Immunogenicity assessment of cell therapies
Examining recent developments with CAR T cells and edited stem cells
Immunogenicity assessment of gene therapies
Recent data on pre-existing reactivity for AAV Advances with redosing
Application of current guidance to novel modalities
What is your product, the vector, the expressed product?

INSTRUCTOR BIOGRAPHIES:

Jim McNally, PhD, CSO, BioAgilytix

2024年10月17日（四） 6:00 - 9:00 pm

SC5: Advice on Putting Together an Integrated Summary of Immunogenicity

The purpose of this workshop is to share experience gained in preparing and reviewing the “Integrated Summary of Immunogenicity (ISI)” for submission in regulatory filings. We will overview examples of the multi-disciplinary information that is most useful for the regulator assessing the scale of risk of undesirable immunogenicity for overall clinical benefit vs. risk. We will also examine the sponsor team's role, the general format of an ISI, and provide examples of how to anticipate and address potential issues (and how to avoid introducing any new ones!) by generating a well-thought-out and constructed integrated summary.

6:00 pm

Advice on Putting Together an Integrated Summary of Immunogenicity

Bonnie Rup, PhD, Biotechnology Consultant, Bonnie Rup Consulting

Background

Information relevant to the assessment of the impact of undesirable immunogenicity of therapeutic proteins on overall clinical benefit vs. risk balance is distributed across many different sections of the regulatory dossier. This has made it difficult for regulatory reviewers to locate the requisite data. Moreover, essential background information to describe the intrinsic immunogenic potential of the molecule, and how extrinsic factors (product quality, patient variables, dose regimen, etc.) might interact to influence clinical manifestations, is often missing. Although there might be valid reasons for applying a particular strategy for evaluating immunogenicity, the sponsor’s rationale is often not clearly explained. For this reason, recently issued FDA and EMA guidance has recommended submitting integrated summary documents in regulatory submissions with the objective of collating the essential information required by the regulatory assessor.

Who Should Attend?
This short course is relevant to anyone who is involved in generating and compiling the input data for immunogenicity--related sections of regulatory dossiers, including CMC, bioanalytical, non--clinical, clinical, and regulatory specialists.

Topics to be Covered Include:

Regulatory expectations
The iterative process
Risk assessment and study planning
Identifying relevant information for the ISI
ISI structure, level of detail and analysis, suggestions for presenting the data

INSTRUCTOR BIOGRAPHIES:

Bonnie Rup, PhD, Biotechnology Consultant, Bonnie Rup Consulting

Bonita Rup is a biopharmaceutical development consultant, providing expert advice on bioanalysis, immunogenicity risk assessment, and related regulatory strategy aspects of biopharmaceutical development. Previously she was Research Fellow and lead for the Immunogenicity Discipline at Pfizer, Assistant Vice President of Protein Bioanalytics in Wyeth, and held various positions directing development and application of immuno-ligand binding assay technologies for PK, immunogenicity and protein impurity analysis, and other aspects of biopharmaceutical development. During her career, she has been involved in multiple regulatory filings during preclinical, clinical development and marketing approval of biopharmaceutical products. She has been a member of AAPS, EIP, European IMI ABIRISK consortium, and Biosafe; with these organizations, she has been a co-author for multiple publications related to monitoring immunogenicity and bioanalysis of therapeutic proteins. Bonnie received her B.S. from University of Massachusetts, Amherst, Ph.D. from University of Texas, Austin, and conducted postdoctoral research at Duke University and University of Rochester, NY.

* 活動內容有可能不事先告知作更動及調整。

Virtual Event 通行證的申請已經結束。
On-Demand only通行證依然持續接受申請。
請透過以下詢問按鍵與我們聯絡。

Choose your language